DIFFERENT PROLIFERATIVE RESPONSE OF HUMAN AND CHIMPANZEE LYMPHOCYTES AFTER CONTACT WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120

被引:22
|
作者
DIRIENZO, AM
FURLINI, G
OLIVIER, R
FERRIS, S
HEENEY, J
MONTAGNIER, L
机构
[1] INST PASTEUR,DEPT RETROVIRUSES,VIRAL ONCOL UNIT,PARIS,FRANCE
[2] CNRS,URA 157,PARIS,FRANCE
关键词
HUMAN IMMUNODEFICIENCY VIRUS; GP120; PROLIFERATION; LYMPHOCYTES;
D O I
10.1002/eji.1830240106
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
T cell functional defects are a common aspect of human immunodeficiency virus (HIV) infection. Moreover, it has been suggested that indirect mechanisms are involved in CD4(+) cell depletion. Unresponsiveness to proliferative stimuli of lymphocytes incubated with HIV particles or with viral proteins is well documented. Nevertheless, drawing a clear picture of the anergy phenomenon is difficult because of several unresolved and controversial questions. Here we report that recombinant gp120 induces anergy in T helper lymphocytes cultured with different stimuli. The proliferative responses to interleukin (IL)-2, IL-4, IL-6, anti-CD2, anti-CD3 and phorbol 12-myristate 13-acetate are inhibited. Moreover, anergic cells show a different distribution in cell cycle phases as compared to control cells, leading us to suggest that the progresion in the cell cycle is hampered and that a pre-mitotic block takes place. Furthermore, since chimpanzees are susceptible to HIV-1 infection without showing immunodeficiency signs, we analyzed the proliferation of chimpanzee lymphocytes without observing anergy in cells preincubated with gp120. Taken together, these results support the hypothesis that anergy plays an important role in HIV infection in vivo.
引用
收藏
页码:34 / 40
页数:7
相关论文
共 50 条
  • [21] Human herpesvirus 8 reactivation and human immunodeficiency virus type 1 gp120
    Lu, C
    Gordon, GM
    Chandran, B
    Nickoloff, BJ
    Foreman, KE
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2002, 126 (08) : 941 - 946
  • [22] CHARACTERIZATION OF A DISCONTINUOUS HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120 EPITOPE RECOGNIZED BY A BROADLY REACTIVE NEUTRALIZING HUMAN MONOCLONAL-ANTIBODY
    THALI, M
    OLSHEVSKY, U
    FURMAN, C
    GABUZDA, D
    POSNER, M
    SODROSKI, J
    JOURNAL OF VIROLOGY, 1991, 65 (11) : 6188 - 6193
  • [23] GALACTOSYL CERAMIDE OR A DERIVATIVE IS AN ESSENTIAL COMPONENT OF THE NEURAL RECEPTOR FOR HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEIN GP120
    BHAT, S
    SPITALNIK, SL
    GONZALEZSCARANO, F
    SILBERBERG, DH
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (16) : 7131 - 7134
  • [24] DELINEATION OF A REGION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120 GLYCOPROTEIN CRITICAL FOR INTERACTION WITH THE CD4 RECEPTOR
    LASKY, LA
    NAKAMURA, G
    SMITH, DH
    FENNIE, C
    SHIMASAKI, C
    PATZER, E
    BERMAN, P
    GREGORY, T
    CAPON, DJ
    CELL, 1987, 50 (06) : 975 - 985
  • [25] NONRANDOM DISTRIBUTION OF GP120 N-LINKED GLYCOSYLATION SITES IMPORTANT FOR INFECTIVITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    LEE, WR
    SYU, WJ
    DU, B
    MATSUDA, M
    TAN, S
    WOLF, A
    ESSEX, M
    LEE, TH
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (06) : 2213 - 2217
  • [26] HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 CHALLENGE OF CHIMPANZEES IMMUNIZED WITH RECOMBINANT ENVELOPE GLYCOPROTEIN GP120
    BERMAN, PW
    GROOPMAN, JE
    GREGORY, T
    CLAPHAM, PR
    WEISS, RA
    FERRIANI, R
    RIDDLE, L
    SHIMASAKI, C
    LUCAS, C
    LASKY, LA
    EICHBERG, JW
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (14) : 5200 - 5204
  • [27] AN N-GLYCAN WITHIN THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120 V3 LOOP AFFECTS VIRUS NEUTRALIZATION
    BACK, NKT
    SMIT, L
    DEJONG, JJ
    KEULEN, W
    SCHUTTEN, M
    GOUDSMIT, J
    TERSMETTE, M
    VIROLOGY, 1994, 199 (02) : 431 - 438
  • [28] Hidden dUTPase sequence in human immunodeficiency virus type 1 gp120
    Abergel, C
    Robertson, DL
    Claverie, JM
    JOURNAL OF VIROLOGY, 1999, 73 (01) : 751 - 753
  • [29] THE CONTROL OF THE ANTIBODY ISOTYPE RESPONSE TO RECOMBINANT HUMAN-IMMUNODEFICIENCY-VIRUS GP120 ANTIGEN BY ADJUVANTS
    BOMFORD, R
    STAPLETON, M
    WINSOR, S
    MCKNIGHT, A
    ANDRONOVA, T
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (10) : 1765 - 1771
  • [30] THE SPECIFICITY OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 TRANSACTIVATOR IS DIFFERENT FROM THAT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    EMERMAN, M
    GUYADER, M
    MONTAGNIER, L
    BALTIMORE, D
    MUESING, MA
    EMBO JOURNAL, 1987, 6 (12): : 3755 - 3760